Advertisement
News
Advertisement

Cerulean Pharma launches ovarian cancer trial

Mon, 07/23/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Cerulean Pharma Inc, a privately-held developer of cancer drugs delivered by tiny nanoparticles, has launched a Phase 2 study of its lead drug candidate in ovarian cancer patients who are resistant to some other drugs. The ovarian cancer study is targeting patients whose cancer has advanced despite treatment with standard platinum therapy.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading